New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
09:09 EDTCERUCerulean announces CRLX101 combination data presented at ASCO
Cerulean Pharma announced that three abstracts on its lead candidate, CRLX101, were included in the 2014 American Society of Clinical Oncology Annual Meeting held in Chicago. An interim analysis of CRLX101 in combination with Avastin in a Phase 1b/2 clinical trial in patients with relapsed renal cell carcinoma, which was previously presented by Stephen Keefe, of the University of Pennsylvania Abramson Cancer Center at the ASCO Genitourinary Cancers Symposium in January, also was included in the ASCO Annual Meeting's electronic compendium of abstracts. This ongoing trial has shown that CRLX101 can be combined safely with Avastin, and preliminary outcomes suggest a clinical benefit in response rate and progression-free survival. The trial is being conducted at the Abramson Cancer Center and Thomas Jefferson University Hospital. The company said, "Collectively, these abstracts demonstrate the potential value of CRLX101 in combination with other cancer treatments across a range of cancers. We're working to advance CRLX101 in combination with other cancer treatments in all three indications, and we expect to launch a randomized trial in relapsed RCC this summer."
News For CERU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 18, 2015
20:19 EDTCERUCerulean participates in lunch meeting with Philadelphia Securities Association
Luncheon meeting with management being held in Philadelphia on April 21 at 11:30 am hosted by Philadelphia Securities Association.
April 13, 2015
07:11 EDTCERUCerulean says publication shows CRLX101 targets breast cancer stem cells
Cerulean Pharma announced the publication of a manuscript in Breast Cancer Research and Treatment, describing preclinical data that demonstrate CRLX101, Cerulean’s lead proprietary investigational drug, targets breast cancer stem cells and impedes resistance to anti-angiogenic therapy in breast cancer mouse models. The results of the study demonstrate that CRLX101, a dual topoisomerase-1 and HIF-1α inhibitor, blocks the HIF-1α mediated increase in cancer stem cells induced by Avastin in a triple-negative breast cancer xenograft mouse model. The up-regulation of HIF-1α by Avastin is believed to be a mechanism of resistance to anti-angiogenic therapy. The combined effects of CRLX101 plus Avastin on cancer stem cells and bulk tumor cells resulted in significant tumor shrinkage and delayed recurrence in this model. The manuscript posits that these data provide a compelling rationale for combining CRLX101 with angiogenic agents in patients with cancer where HIF-1α mediated increases in cancer stem cells may play a role in chemoresistance. The article, “CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to anti-angiogenic therapy in mouse models of breast cancer” by Conley, et al, was published in the April 2015 issue of Breast Cancer Research and Treatment.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use